Inhibits ACE with a Ki of 1.6 uM, and targets B2 bradykinin receptor (BDKRB2). Provokes contraction of smooth muscle preparation (ileum). In vivo, induces an early hyperalgesic effects in living rats after intraplantar injection (By similarity). Inhibits the bradykinin-induced in vitro relaxation of rat arterial smooth muscle and constriction of intestinal smooth muscle. May target bradykinin receptors (BDKRB). Expressed by the skin glands. The measured mass is that of bradykinin inhibitor peptide DV-28. Belongs to the bradykinin-related peptide family.